The DATA-Switch is a follow-up study of the DATA trial, a randomised, controlled, single-centre trial that initially assessed the efficacy of denosumab, teriparatide, or Swjtch in postmenopausal women. BMD gain was greatest in the group that received combined teriparatide plus denosumab treatment for the first 24 months.
Discontinuing teriparatide and denosumab, however, in rapidly declining bone mineral density. In this DATA-Switch study, we aimed to assess the changes in bone mineral density in postmenopausal osteoporotic women who transitioned between eprawny.biz by:.
02/07/ · This randomised controlled trial (DATA-Switch) is a preplanned extension of the denosumab and teriparatide administration study (DATA), in which 94 postmenopausal osteoporotic women were randomly assigned to receive 24 Data Switch Study of teriparatide (20 mg daily), denosumab (60 mg every 6 months), or both eprawny.biz by:.